Physician profile
Yong Park
NPI 1760582712
$77,883.78
in general payments reported to CMS, 2019-2025
51 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $3,915 · 2021: $11K · 2022: $5,824 · 2023: $7,007 · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $7,656 · Travel and Lodging: $1,665 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,300.00 |
| Food and Beverage | $7,655.51 |
| Travel and Lodging | $1,664.83 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $39,156.20 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $27,109.35 | 2022-2025 | Epidiolex, Xywav |
| Ucb, INC. | $2,341.12 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $1,416.56 | 2020-2025 | Xcopri |
| Neurelis, INC. | $1,350.51 | 2020-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $947.84 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $713.15 | 2019-2022 | |
| Eisai INC. | $692.47 | 2019-2023 | |
| Harmony Biosciences LLC | $593.20 | 2020-2025 | Wakix |
| Catalyst Pharmaceuticals, INC. | $582.92 | 2023-2025 | Fycompa |
| Livanova USA, INC. | $232.54 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $219.31 | 2022-2025 | Ultomiris, Soliris |
| Aquestive Therapeutics, INC. | $208.16 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $199.95 | 2023-2025 | Daybue |
| Neuropace, INC. | $195.27 | 2019-2023 |
Show all 49 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.